Take­da slammed with sur­prise PhI­II fail­ure on 'break­through' blood can­cer drug, im­plod­ing launch plans

One of Take­da’s “break­through” drugs has hit a snag.

In the Phase III PAN­THER study, pevonedi­s­tat — which works by in­hibit­ing the NEDD8-ac­ti­vat­ing en­zyme — failed the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER